Osimertinib in Treating CNS Metastases From Lung Cancer
A pooled subgroup analysis of the phase II AURA studies demonstrated the safety and efficacy of osimertinib in the treatment of central nervous system (CNS) metastases in patients with T790M-positive non–small cell lung cancer (NSCLC). Given the incidence of CNS metastases may reach beyond 45% in these patients 3 years after diagnosis, “there is an increasing need for therapeutics that can ensure control within the sanctuary CNS site,” stated lead author Glenwood Goss, MD, of the Ottawa Hospital Cancer Centre. The study was published in Annals of Oncology.
The authors evaluated 128 patients for at least 1 measurable lesion through brain scans. A total of 50 patients were eligible for analysis in the study response set. The primary outcome was objective response rate, measured through blinded independent central neuroradiology review. Secondary analysis included disease control rates.
Median progression-free survival and duration of response were not met. The confirmed CNS objective response rate was 54%, and the disease control rate was 92%. Prior radiotherapy to the brain did not seem to affect patient responses to osimertinib. In addition, 75% of patients were estimated to remain in response at 9 months.
The authors concluded: “Osimertinib offers an additional line of treatment for patients with T790M-positive NSCLC and CNS metastases.”